EDAP TMS SA Celebrates Milestones in Revenue and Innovation
Overview of EDAP TMS SA's Exceptional Performance
EDAP TMS SA (NASDAQ: EDAP) has recently announced an impressive financial performance for the year 2024, marking a historic peak in HIFU (High-Intensity Focused Ultrasound) revenue. With a remarkable total of USD 25.7 million achieved throughout the year, this figure reflects a notable 15.3% increase compared to 2023.
The fourth quarter alone showcased a record HIFU revenue of USD 9.3 million, representing a sharp 15.0% rise from the preceding year. These positive financial metrics underscore the growing acceptance and effective application of HIFU treatments in clinical settings.
Growth in U.S. Focal One Procedures
In 2024, the U.S. market for Focal One HIFU procedures witnessed an astounding growth of 51% year-on-year. This surge is indicative of the increasing recognition among physicians and patients about the benefits of HIFU technology in treating prostate cancer.
EDAP TMS's Focal One system was also awarded the CE Mark for treating deep infiltrating endometriosis, further diversifying its application and demonstrating its effectiveness across different medical conditions.
Landmark Clinical Studies and Innovations
Recently, the HIFI study results were published in the prestigious journal European Urology, showcasing favorable outcomes of Focal One Robotic HIFU when compared to traditional surgical methods for managing prostate cancer. This pivotal research has not only validated the efficacy of HIFU treatments but could also significantly influence the treatment landscape for prostate cancer.
The company has also initiated its first Phase I/II study on patients suffering from Benign Prostatic Hyperplasia (BPH) using the Focal One Robotic HIFU, further asserting EDAP TMS's commitment to expanding the clinical applications of its technology.
Strategic Focusing on Core Business
According to CEO Ryan Rhodes, EDAP TMS is concentrating its resources on enhancing its Focal One business while exploring emerging high-growth opportunities in therapeutic HIFU. This focused approach aims to optimize investment strategies and attain significant value for patients and shareholders alike.
As part of this strategy, the company recently made key appointments to its Board of Directors, welcoming executive talents with extensive experience in medical device development. These strategic additions aim to bolster the company’s leadership in innovative treatment solutions.
Financial Highlights: Fourth Quarter and Full-Year Results
The fourth quarter financial reports reflected a total global revenue of EUR 20.3 million (USD 21.5 million), marking a 3.6% growth compared to the fourth quarter of 2023, which saw EUR 19.6 million (USD 21.3 million).
The HIFU segment contributed EUR 8.8 million (USD 9.3 million) for the fourth quarter of 2024, up from EUR 7.5 million (USD 8.1 million) in the same quarter of the previous year. This growth trajectory is supported by a 31% increase in Focal One procedures in the U.S.
Consolidated Financial Performance Summary
For the entire year of 2024, total worldwide revenue achieved EUR 64.1 million (USD 69.2 million), indicating a 6.1% increase over 2023’s revenue. The gross profit reached EUR 26.6 million (USD 28.7 million), with a gross profit margin improvement to 41.4% for the year.
Despite the substantial gains in specific segments, the overall operating loss for the year was EUR 20.5 million (USD 22.2 million), reflecting ongoing investments in business expansions.
Future Outlook and Conference Call
In the upcoming months, EDAP TMS plans to engage with the medical community at the American Urology Association Meeting, where it will showcase its advancements and innovations in urology-focused treatments.
Investors and interested stakeholders are invited to join the conference call where management will discuss these results in further detail, alongside expectations for the future.
For more inquiries or detailed information, please reach out to Blandine Confort — Investor Relations / Legal Affairs at EDAP TMS SA.
Frequently Asked Questions
What is HIFU and how does it work?
HIFU stands for High-Intensity Focused Ultrasound, a non-invasive medical procedure that uses focused ultrasound waves to target and destroy tissue, primarily used in cancer treatment.
What recent approvals has the Focal One system received?
The Focal One system recently received CE Mark certification for the treatment of deep infiltrating endometriosis.
How has EDAP TMS SA performed financially in 2024?
In 2024, EDAP achieved record HIFU revenue of USD 25.7 million, marking a 15.3% increase over the previous year.
What recent clinical trial results has EDAP TMS SA announced?
EDAP announced positive outcomes from the HIFI study published in European Urology, showing how Focal One compares favorably to conventional surgery in prostate cancer management.
What is the company's future direction?
EDAP TMS intends to focus on core HIFU business growth while looking towards innovative therapeutic opportunities, enhancing its market position and shareholder value.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
